Connect with us

News

Agetech World’s latest innovation & investment round-up

Published

on

We round up the latest ageing and longevity investment news.

Regenerative cellular medicine company Celularity Inc has secured a US$10m financing package to support its healthy-ageing innovations.

The NASDAQ-listed business which focuses on addressing age-related and degenerative diseases secured the financing from Philip Barach, co-founder and former president of US investment house DoubleLine Capital.

“This closing strengthens Celularity’s financial position and provides meaningful flexibility as we continue to analyse and prioritise our platform and pipeline,” said Dr Robert Hariri, chairman and chief executive officer of Celularity. 

Celularity develops and commercialises off-the-shelf, allogeneic cell therapies and advanced biomaterial products derived from the postpartum placenta.

Dr Hariri added, “In the new year, we intend to more fully articulate Celularity’s corporate strategy, including our plan to align our scientific capabilities with long-term opportunities in longevity and age-related disease. 

“Our objective is to reshape Celularity into a durable, disciplined organisation that can translate innovation into sustainable value for patients and shareholders.”

GlycanAge boost

UK innovators GlycanAge has raised EUR7.4m (US$8.7m) as it looks to bring its diagnostics technology into mainstream care.

The investment round, totalling US$10m, is led by Fifth Quarter Ventures with participation from Guinness Ventures, BrightCap Ventures, South Central Ventures, Impetus Capital, Vesna Deep Tech VC and Lightfield Equity.

Its existing backers, which include LaunchHub Ventures and Kadmos Capital, have delivered pro-rata support, too. In 2024, GlycanAge raised a US€3.9m seed round.

Glycans are complex sugars that coat cells and many proteins, helping control immunity and cell signalling.

GlycanAge technology reads these signals to estimate biological age and deliver timely warnings of disease development.

Prof Gordan Lauc, co-founder and chief scientific officer of GlycanAge, said: “Our goal is to make glycan testing part of standard preventive diagnostics, where everyone over the age of 30 can access it through their healthcare provider.” 

Chinese researchers say they have developed a new model capable of predicting the degree of ageing in individual human organs, allowing for a more precise assessment of how different organs age over time.

US$16.5m boost for biomarker start-up

The research team at Xi’an Jiaotong University said previous studies had largely focused either on general characteristics of overall ageing, which made it difficult to identify distinct genetic patterns and molecular pathways linked to the ageing of specific organs.

In the new study, the researchers identified 554 genes associated with a high risk of organ ageing, saying this allowed their model to lead to the early screening of high-risk groups, and identify causal links between organ ageing and chronic diseases, thereby supporting disease prevention efforts.

Glucose biomarker startup Liom has secured an additional US$16.5m for its Series A financing, bringing the round to US$48m, as it succeeded in shrinking its non-invasive, biomarker-monitoring platform to wearable size. 

The Swiss company is developing a glucose-monitoring wearable, capable of providing continuous metabolic insight – without requiring needles or user calibration – and is targeting a commercial launch in 2028.

The vast majority of glucose monitoring devices currently rely on microneedles inserted under the skin.

Bank secures longevity boost

Almost 40 per cent of respondents to Life Time’s annual report identify that longevity is the wellness trend most likely to define 2026.

Findings from Life Time’s annual health and wellness survey, indicate strength training, and longevity health habits, are key priorities for Americans in 2026.

“People are training more intentionally, to feel and perform better for longer – and pairing that with smarter recovery and objective health metrics,” said Danny King, director of recovery and performance at Life Time, one of America’s leading healthy lifestyle brands. 

The increasing longevity of its former employees has seen Lloyds Banking Group Pensions Trustees Limited enter into three new longevity insurance and reinsurance transactions, safeguarding a further £4.8bn of pension liabilities against the risk of unexpected increases in member life expectancy.

Vicky Paramour, trustee director and chair of the investment & funding committee, said: “We are pleased to have successfully completed these transactions, which further reduce the Schemes’ exposure to longevity risk and make the schemes more secure to the benefit of all members.”

News

Study shows clear link between CTE and dementia risk

Published

on

A new study says CTE should be recognised as a cause of dementia, with those in the most advanced stages facing a 4.5-fold higher lifetime risk.

Chronic traumatic encephalopathy (CTE) is a degenerative brain condition seen in some athletes.

Linked to repeated head impacts, it can cause memory loss, mood changes, poor coordination and suicidal thoughts. Diagnosis is only possible after death.

People with the most advanced CTE were 4.5 times more likely to develop dementia during life than people without CTE, researchers found.

Many former NHL and NFL players have been posthumously diagnosed with CTE, including Junior Seau, Frank Gifford and Ken Stabler.

The study from researchers at the Boston University CTE Center provides what the centre describes as the clearest evidence yet linking CTE to dementia risk.

The centre says these findings indicate CTE should be known as a cause of dementia.

“This study provides evidence of a robust association between CTE and dementia as well as cognitive symptoms, supporting our suspicions of CTE being a possible cause of dementia,” said Dr Michael Alosco, an associate professor of neurology and co-director of clinical research at the BU CTE Center.

“Establishing that cognitive symptoms and dementia are outcomes of CTE moves us closer to being able to accurately detect and diagnose CTE during life, which is urgently needed.”

Researchers studied brain tissue from more than 600 donors, the majority men.

The donors, primarily contact sport athletes, had known exposure to repetitive head impacts, but none had Alzheimer’s disease, Lewy body disease or frontotemporal lobar degeneration.

They found that 366 male donors had CTE. After examining the donor brains, they calculated the odds of developing dementia across CTE stages I to IV.

Donors with stages III and IV had the worst cognitive and functional symptoms, regardless of age or history of substance use treatment.

Lower stages were not associated with dementia, cognitive impairment or functional decline.

The team also found no link between less severe CTE and changes in mood or thinking, suggesting observed changes may stem from other effects of repetitive head impacts or unrelated medical or environmental factors.

“Understanding which brain changes drive cognitive decline is essential,” said Dr Richard Hodes, director of the National Institute of Health’s National Institute on Aging.

“This study shows that only severe CTE has a clear link to dementia, which provides an important distinction for researchers, healthcare providers and families.”

The study also found that dementia due to CTE is often misdiagnosed as Alzheimer’s disease.

Both conditions are marked by abnormal tau proteins that build up in brain cells and affect blood vessels, although the tau differs in each disease.

Of donors with CTE who had received a dementia diagnosis during life, 40 per cent were told they had Alzheimer’s disease but showed no evidence of it at autopsy.

A further 38 per cent of families were told the cause of dementia was unknown or could not be specified.

Continue Reading

News

ATW’s research round-up: new Alzheimer trigger identified, UK university targets longevity. fibre not protein?…and more

Published

on

A UK university will become one of the first in the country to make improving the health and well-being of the elderly one of its six ‘mission-led’ research priorities.

Bournemouth University’s choice to focus on pensioners is partly the result of the Labour Government’s wish for universities to specialise, whilst also reflecting the area’s demographics – the south-coast city has one of the one of the oldest populations in the world.

“Our demographics are much older than other places – about 10 years older on average compared to the rest of the UK,” explained Tom Wainwright, professor of orthopaedics at Bournemouth.

Vary your exercise

The university’s Orthopaedic Research Institute is already heavily involved in work with the surrounding area and its recently published study, in The Lancet, showed that over-65s with osteoarthritis who undertook group-based cycle classes enjoyed much better outcomes than those receiving one-to-one physiotherapy.

Research published in leading British doctors’ publication the BMJ Journal, which tracked 100,000 people over the last 30 years, has shown that mixed exercise routines can have a significant impact on overall health and longevity.

The study tracked the cohorts exercise habits over three decades and found that participants who engaged in the highest variety of exercises had a 19% lower risk of death, compared to those who engaged in the lowest variety.

Benefits were even bigger when looking at specific causes like heart disease, cancer, and respiratory illness, with risk reductions ranging from 13 to 41 percent.

“People naturally choose different activities over time based on their preferences and health conditions,” says Yang Hu, corresponding author and research scientist in the Harvard TH Chan Department of Nutrition.

“When deciding how to exercise, keep in mind that there may be extra health benefits to engaging in multiple types of physical activity, rather than relying on a single type alone.”

US researchers have identified over five dozen new potential blood-based metabolites which could predict a Type 2 diabetes risk, years in advance.

Key Alzheimer trigger identified

Scientists at Mass General Brigham and Albert Einstein College of Medicine, followed 23,634 participants for up to 26 years and over that time analysed 469 metabolites in blood samples, alongside additional genetic, diet and lifestyle data.

In doing so they identified 235 metabolites associated with higher or lower diabetes risk, including 67 new molecules previously unreported.

The researchers say their work supports a shift toward precision prevention strategies which are more reliable than current indicators such as BMI or family history.

Further research into the Alzheimer’s predicting APOE (apolipoprotein E) gene has left UK researchers with renewed conviction of their ability to develop preventive measures, earlier in life.

Researchers at University College London analysed nearly 470,000 people across four major studies, focusing on participants aged 60 and older with confirmed Alzheimer’s diagnoses and genetic data.

Whilst previous studies had identified the ε4 allele of APOE as the one most predictive of Alzheimer’s development the UCL researchers also highlighted how allele ε3 may also carry a significant risk

Dr Dylan Williams, the study’s lead author, explained that the APOE gene’s contribution to the prevalence of Alzheimer’s has been significantly underestimated for a long time, and that the ε3 allele has historically been misunderstood as having a neutral effect on risk.

He said: “Intervening on the APOE gene, or the molecular pathway between the gene and Alzheimer’s, could have huge potential for preventing or treating a large majority of cases.”

Fibre first

Researchers say that fibre – found in beans, lentils, chia seeds, oats, bran, and certain fruits – is emerging as the ‘new hero’ of nutrition science.

Longevity expert Dr Vassily Eliopoulos, MD, who trained at Cornell, highlights how protein has ruled diet trends for years, but says fibre is now stepping into the spotlight.

“Everyone’s chasing protein, but the next big longevity macro is fibre. And fibre might be the most under-appreciated longevity nutrient that you’re missing daily.”

Explaining why fibre plays such a crucial role, he highlights the connection between gut health and overall well-being.

“Here’s the secret, your gut microbes eat what you don’t digest. These microbes convert fibre into powerful compounds that protect the body. They turn fibre into short-chain fatty acids, which act as your body’s natural anti-inflammatory molecules,”

Dr Eliopoulos highlights how chronic inflammation is closely linked to ageing and disease and he recommends aiming for 30 to 40 grams of fibre a day.

Continue Reading

News

Assisted dying should be ‘gradually’ extended to dementia, author Ian McEwan says

Published

on

Author Ian McEwan said legalised assisted dying should be gradually extended to people with dementia.

Speaking at a public book event in London on 28 January, he criticised attempts to block the UK’s assisted dying bill, citing more than 1,000 amendments.

Supporters believe it is near impossible for it to pass the House of Lords before the end of the session in May due to alleged filibustering.

If passed, the bill would legalise assisted dying in England and Wales for adults with less than six months to live.

“I like it when some bishop says on the radio: ‘It’s the thin end of the wedge,’ and I think yes, it is the thin end of the wedge,” said McEwan, who is a patron of Dignity in Dying.

“Certain groups are missing from it, such as those with dementia. It has to be physical pain.

“My guess is that if we pushed it through with all the protections around it – of doctors and dispassionate people making judgements – we’ll look back on this and think, ‘Why did we ever let people die in agony?'”

Asked if he would add an amendment to extend assisted dying to dementia sufferers, McEwan said: “Gradually, yeah, I would. But I think it does require a lot more thought and the idea of living wills.”

“My mother used to say to me: ‘If I ever become really terrible, I’d like you to finish me off.’ But of course, that’s to commit murder as things stand. Imagine standing up in court and saying: ‘Well, she did say when we were on the beach 20 years ago…'”

McEwan spoke about dementia’s impact on his family.

His mother Rose had dementia, as well as his brother-in-law and another close family member.

“By the time my mother was well advanced and could not recognise anyone, she was dead. She was alive and dead all at once.

“It was a terrible thing. And the burden on those closest is also part of the radioactive damage of it all.”

McEwan was speaking at St Martin-in-the-Fields church in central London, as part of its Conversation series, discussing his latest book, What We Can Know, in which dementia is a major theme.

He has also written about dementia in previous novels, Lessons and Saturday.

Continue Reading

Trending

Agetech World